The interstitial lung disease market is expected to experience significant growth during the forecast period, supported by the continued use of established and supportive treatments, including corticosteroids, immunosuppressants, biologics, and adjunctive therapies such as cough suppressants. In parallel, the development and anticipated introduction of promising pipeline therapies, including seralutinib (Gossamer Bio/Chiesi Farmaceutici), L606 (Liquidia Corporation), N-115 (Emphycorp), efzofitimod (aTyr Pharma), and others, are broadening treatment options by targeting different disease mechanisms. These developments are expected to contribute to continued market expansion and therapeutic innovation.
The Interstitial Lung Disease Market is anticipated to expand at a CAGR of 8.7% during 2026–2036, primarily supported by the expected launch of emerging therapies and ongoing developments across the ILD treatment landscape.
The recently published Interstitial Lung Disease Market Insights report offers an extensive assessment of existing treatment practices, emerging ILD therapies, individual therapy market shares, and historical and forecasted market size from 2022 to 2036. The analysis covers the major markets comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Interstitial Lung Disease Market Summary
- The interstitial lung disease market size across the 7MM was estimated at approximately USD 6 billion in 2025.
- The United States represented the largest share of the ILD treatment market in 2025, accounting for 83%, followed by the EU4, the United Kingdom, and Japan.
- The total number of diagnosed prevalent ILD cases across the 7MM was approximately 1.3 million in 2025.
- Leading companies involved in the development of innovative ILD therapies include GSK, Insmed, Gossamer Bio, Chiesi Farmaceutici, Liquidia Corporation, Bristol-Myers Squibb, Emphycorp, aTyr Pharma, PureTech Health, Endeavor Biomedicines, Avalyn Pharma, and others.
- Important ILD therapies currently being evaluated in clinical development include Belimumab (BENLYSTA), Treprostinil Palmitil Inhalation Powder (TPIP), Seralutinib, L606 (Treprostinil Liposome Inhalation Suspension), Admilparant (BMS-986278), N115 (Nonsteroidal Nasal Spray), Efzofitimod, Deupirfenidone (LYT-100), Taladegib (ENV-101), AP01 (Inhaled Pirfenidone), and others.
- These emerging therapies are expected to enter the ILD market during the forecast period and potentially alter the competitive and treatment landscape.
- By 2036, JASCAYD (nerandomilast tablets) is estimated to generate the highest revenue among ILD therapies in the 7MM.
Discover which segment is expected to dominate the ILD market @ Interstitial Lung Disease Market Sample Request
Key Factors Driving the Growth of the Interstitial Lung Disease Market
Rising Prevalence of ILDs
The increasing incidence of conditions such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD, and occupational lung diseases is contributing to a larger ILD patient population worldwide.
Advances in Diagnostic Technologies
Progress in diagnostic approaches, including high-resolution computed tomography, pulmonary function testing, and biomarker research, is supporting earlier and more accurate identification of ILD cases.
Growing Disease Awareness and Screening
Greater awareness among physicians, together with increased patient education, is helping improve disease recognition, diagnosis, and identification of ILD cases at earlier stages.
Launch of Emerging ILD Therapies
The ILD market is expected to undergo further changes with the anticipated introduction of emerging therapies, including Belimumab (BENLYSTA) from GSK, Treprostinil Palmitil Inhalation Powder (TPIP) from Insmed, Seralutinib from Gossamer Bio/Chiesi Farmaceutici, L606 from Liquidia Corporation, Admilparant (BMS-986278) from Bristol-Myers Squibb, N115 from Emphycorp, Efzofitimod from aTyr Pharma, Deupirfenidone (LYT-100) from PureTech Health, Taladegib (ENV-101) from Endeavor Biomedicines, AP01 (Inhaled Pirfenidone) from Avalyn Pharma, and others.
According to Ramandeep Singh, Senior Consultant of Forecasting at DelveInsight, the ILD therapeutic pipeline is moving beyond traditional antifibrotic and broad immunosuppressive approaches toward targeted biologics, novel small molecules, and advanced inhaled drug-delivery technologies. Several mid- and late-stage programs are focused on mechanisms involving immune dysregulation, fibrotic signaling, and pulmonary vascular remodeling.
BENLYSTA, developed by GSK, represents an emerging B-cell-targeted approach for autoimmune-driven ILD, particularly systemic sclerosis-associated ILD and connective tissue disease-associated ILD.
Interstitial Lung Disease Market Analysis
The ILD treatment landscape continues to face several challenges while also presenting opportunities for new therapies:
- Approved antifibrotic treatments are commonly associated with gastrointestinal, hepatic, and tolerability-related adverse effects, which may result in dose modifications or treatment discontinuation.
- The requirement for long-term daily oral treatment can create adherence challenges, particularly among elderly patients and individuals with underlying autoimmune disorders.
- Inhaled prostacyclin therapies used for ILD-associated pulmonary hypertension, such as TYVASO, can also present challenges associated with device-based administration.
- Market revenue growth is increasingly influenced by the uptake of high-value and differentiated therapies, including antifibrotics and pulmonary hypertension-targeted treatments such as OFEV and TYVASO/TYVASO DPI, rather than disease prevalence alone.
- The ILD pipeline encompasses a broad range of next-generation antifibrotic agents, immunomodulators, and lung-directed drug-delivery platforms intended to improve efficacy, tolerability, safety, and phenotype-specific outcomes.
- Important mid- and late-stage candidates include taladegib (ENV-101), admilparant (BMS-986278), and seralutinib, along with immune-targeting candidates such as belimumab (BENLYSTA) and efzofitimod.
- Inhaled and localized delivery approaches, including TPIP, L606, and AP01, are being developed with the objective of increasing drug exposure in the lungs while potentially reducing systemic effects.
- New modalities such as N115, a nonsteroidal nasal spray, are further expanding the range of therapeutic mechanisms being explored in ILD.
Learn more about the leading companies working on IPF @ Interstitial Lung Disease Treatment Market
Interstitial Lung Disease Competitive Landscape
The ILD pipeline includes a diverse group of therapies being investigated by pharmaceutical and biotechnology companies. Key candidates include Belimumab (BENLYSTA) (GSK), Treprostinil Palmitil Inhalation Powder (TPIP) (Insmed), Seralutinib (Gossamer Bio/Chiesi Farmaceutici), L606 (Liquidia Corporation), Admilparant (BMS-986278) (Bristol-Myers Squibb), N115 (Emphycorp), Efzofitimod (aTyr Pharma), Deupirfenidone (LYT-100) (PureTech Health), Taladegib (ENV-101) (Endeavor Biomedicines), AP01 (Inhaled Pirfenidone) (Avalyn Pharma), and others.
GSK’s Belimumab (BENLYSTA)
Belimumab (BENLYSTA) is a B-lymphocyte stimulator (BLyS)-targeting inhibitor that binds to soluble BLyS, a key factor involved in B-cell survival. As a fully human monoclonal antibody, it inhibits BLyS-mediated survival of B cells, including autoreactive B cells, and limits their development into immunoglobulin-producing plasma cells.
Belimumab is currently being evaluated in advanced-stage Phase II/III and Phase III clinical trials for systemic sclerosis-associated ILD (SSc-ILD) and connective tissue disease-associated ILD (CTD-ILD). Its development reflects the increasing interest in B-cell-directed immunomodulatory approaches designed to preserve lung function and slow fibrotic disease progression.
Gossamer Bio/Chiesi Farmaceutici’s Seralutinib
Seralutinib is an inhaled inhibitor targeting PDGFRα/β, CSF1R, and c-KIT and is formulated as a dry powder for inhalation. The therapy is being developed for potential use in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia Corporation’s L606
L606, developed by Liquidia Corporation in collaboration with Pharmosa Biopharm, is an investigational liposomal inhalation formulation of treprostinil designed to provide sustained drug release. The formulation is intended to improve pulmonary delivery of treprostinil in patients with PAH and PH-ILD.
Insmed’s Treprostinil Palmitil Inhalation Powder
Treprostinil palmitil inhalation powder (TPIP) is a dry-powder prodrug formulation in which treprostinil is esterified to a 16-carbon chain. It represents a potentially differentiated prostanoid treatment being investigated for PAH, PH-ILD, and other serious pulmonary conditions.
TPIP is administered through a capsule-based inhalation device and remains an investigational therapy that has not received worldwide approval for any indication.
The anticipated introduction of these emerging ILD therapies could significantly influence the market landscape over the coming years. As these therapies progress through development and potentially receive regulatory approvals, they may introduce new treatment approaches, contribute to evolving standards of care, and create further opportunities for innovation across the ILD market.
To learn more about late-stage ILD therapies @ Interstitial Lung Disease Medication
Recent Developments in the Interstitial Lung Disease Market
- March 2026: United Therapeutics reported that the Phase III TETON-1 trial evaluating inhaled treprostinil achieved its primary endpoint in patients with idiopathic pulmonary fibrosis (IPF). The results indicated an improvement in lung function measured by FVC and supported the potential expansion of the therapy beyond PH-ILD into broader ILD indications.
- December 2025: PureTech Health announced the successful completion of its End-of-Phase II (EOP2) meeting with the US FDA concerning the development of deupirfenidone (LYT-100) for IPF.
- December 2025: The US FDA approved nerandomilast (JASCAYD) tablets for the treatment of PPF in adults.
- November 2025: Endeavor BioMedicines announced that the EMA granted PRIME designation to its investigational therapy taladegib for the treatment of IPF.
What is Interstitial Lung Disease?
Interstitial lung disease (ILD) represents a broad group of pulmonary disorders that primarily affect the interstitium, the delicate tissue surrounding the air sacs of the lungs. In ILD, this tissue can become inflamed and/or scarred, reducing lung flexibility and affecting the transfer of oxygen into the bloodstream.
ILD can result from prolonged exposure to environmental or occupational irritants, autoimmune diseases, certain medications, and infections. However, the underlying cause is not always identified, as occurs in idiopathic pulmonary fibrosis.
Common symptoms include persistent dry cough, shortness of breath, and fatigue, which may progressively worsen. Although many ILD forms are chronic and progressive, timely diagnosis and appropriate disease management may help slow progression and support patients' quality of life.
Interstitial Lung Disease Epidemiology Segmentation
The interstitial lung disease epidemiology analysis provides an assessment of the historical and current patient population as well as projected epidemiological trends across the major markets.
According to DelveInsight estimates, the United States had nearly 520,000 diagnosed prevalent cases of ILD in 2025.
The Interstitial Lung Disease Market Report provides epidemiological analysis covering 2022–2036 across the leading markets, including:
- Diagnosed Prevalent Cases of ILD
- Gender-specific Cases of ILD
- Type-specific Cases of ILD
- Treated Cases of ILD
Download the report to understand leading therapies for pulmonary fibrosis @ Interstitial Lung Disease Market Report
Interstitial Lung Disease Market Report Metrics
- Study Period: 2022–2036
- Market Report Coverage: 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
- Market CAGR: 8.7%
- Market Size in 2025: USD 6 billion
- Key Companies: GSK, Insmed, Gossamer Bio, Chiesi Farmaceutici, Liquidia Corporation, Bristol-Myers Squibb, Emphycorp, aTyr Pharma, PureTech Health, Endeavor Biomedicines, Avalyn Pharma, United Therapeutics, Boehringer Ingelheim, Roche, and others
- Key Therapies: Belimumab (BENLYSTA), Treprostinil Palmitil Inhalation Powder (TPIP), Seralutinib, L606, Admilparant (BMS-986278), N115, Efzofitimod, Deupirfenidone (LYT-100), Taladegib (ENV-101), AP01, TYVASO/TYVASO DPI/TREPROST, YUTREPIA, JASCAYD, OFEV, ACTEMRA, and others
Scope of the Interstitial Lung Disease Market Report
- Interstitial Lung Disease Therapeutic Assessment: Assessment of currently marketed and emerging ILD therapies.
- Interstitial Lung Disease Market Dynamics: Conjoint analysis of emerging ILD drugs.
- Competitive Intelligence Analysis: SWOT analysis and market-entry strategies.
- Interstitial Lung Disease Market Unmet Needs: Assessment of unmet needs, KOL perspectives, analyst views, market access, and reimbursement.
Discover more about unmet needs in ILD @ Interstitial Lung Disease Clinical Trials
Table of Contents
- Interstitial Lung Disease Market Key Insights
- Interstitial Lung Disease Market Report Introduction
- Interstitial Lung Disease Market Overview at a Glance
- Epidemiology and Market Methodology
- Executive Summary
- Key Events
- Disease Background and Overview
- Epidemiology and Patient Population
- Interstitial Lung Disease Patient Journey
- Marketed Interstitial Lung Disease Therapies
- Emerging Interstitial Lung Disease Therapies
- Interstitial Lung Disease Market - Seven Major Market Analysis
- Key Opinion Leaders’ Views on ILD
- Interstitial Lung Disease Market SWOT Analysis
- Interstitial Lung Disease Market Unmet Needs
- Interstitial Lung Disease Market Access and Reimbursement
- Bibliography
- Interstitial Lung Disease Market Report Methodology
Related Reports
Interstitial Lung Disease Clinical Trial Analysis
The Interstitial Lung Disease Pipeline Insight – 2026 report provides a detailed overview of the ILD pipeline, covering therapies in both clinical and non-clinical development. Key companies assessed include AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical, Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring, AstraZeneca, and others.
Pulmonary Hypertension Associated With Interstitial Lung Disease Market
The Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2034 report provides comprehensive information on the disease, historical and forecasted epidemiology, individual therapy market shares, and key PH-ILD companies, including Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, Halo Biosciences, Respira Therapeutics, Gossamer Bio, and others.
About DelveInsight
DelveInsight is a business consulting and market research company dedicated to the life sciences industry. The company provides pharmaceutical organizations with comprehensive, end-to-end solutions designed to support business performance and strategic decision-making. DelveInsight also provides access to healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.
Contact US
Kanishk